A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
Prostatic Neoplasms
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 696 (final count)
- Started
- Sep 23, 2020
- Main results expected
- Jan 7, 2025
- Fully finished
- Nov 1, 2027
- Results posted
- Jan 22, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator
Measured over: From date of randomization (Day -3 to Day 1) up to approximately 49 months
HRR Effector Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator
Measured over: From date of randomization (Day -3 to Day 1) up to approximately 49 months
All HRR: Radiographic Progression-free Survival (rPFS) Assessed by Investigator
Measured over: From date of randomization (Day -3 to Day 1) up to approximately 49 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04497844 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC